| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Molecular Pathology Unit, Massachusetts General Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02129 [N. M., W-h. Y., I. S.], and National Cancer Institute, Bethesda, Maryland 20892 [V. P., M. T.]
Recent evidence suggests that one mechanism whereby cytotoxic drugs, such as doxorubicin, kill tumors is the induction or up-regulation of Fas ligand (FasL) expression on the tumor cell surface. The ensuing engagement of Fas by FasL on adjacent cells leads to apoptosis. However, despite cytotoxic drug-induced FasL expression, Fas-sensitive tumors frequently resist chemotherapy, suggesting that they may possess a mechanism that prevents or inactivates Fas-FasL interactions. In the present work, we addressed the involvement of the FasL/Fas signaling pathway in doxorubicin-induced apoptosis and the ability of matrix metalloproteinases (MMPs) to proteolytically cleave FasL in tumor cells. Doxorubicininduced apoptosis was inhibited by expression of soluble Fas or incubation of the tumor cells with MMP-7 but not with MMP-2 or MMP-9. Resistance to doxorubicin was also induced by expression in the tumor cells of constitutively active MMP-7 but not of a catalytically inactive mutant. Conversely, inhibition of MMP-7 expression in tumor cells by transfection of MMP-7 cDNA in antisense orientation resulted in sensitization to doxorubicin. MMP-7 efficiently cleaved recombinant FasL in vitro and reduced cell surface FasL expression. Our observations provide evidence that one mechanism whereby MMP-7 may promote tumor survival and resistance to doxorubicin is by cleaving FasL and reducing its effectiveness in triggering Fas-mediated apoptosis.
This article has been cited by other articles:
|
|
 |
|
  P. K. Wu, W. M. Chen, C. F. Chen, O. K. Lee, C. K. Haung, and T. H. Chen Primary Osteogenic Sarcoma with Pulmonary Metastasis: Clinical Results and Prognostic Factors in 91 Patients Jpn. J. Clin. Oncol., June 12, 2009; (2009) hyp057v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Higashi, M. Oeda, K. Yamamoto, and K. Miyazaki Identification of Amino Acid Residues of Matrix Metalloproteinase-7 Essential for Binding to Cholesterol Sulfate J. Biol. Chem., December 19, 2008; 283(51): 35735 - 35744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors Cancer Res., February 15, 2008; 68(4): 1170 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Accordi, S. Pillozzi, M. C. Dell'Orto, G. Cazzaniga, A. Arcangeli, G. t. Kronnie, and G. Basso Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation J. Biol. Chem., October 5, 2007; 282(40): 29384 - 29393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Johansson, M. A. Taylor, M. Jagodic, K. Tus, J. D. Schatzle, E. K. Wakeland, and M. Bennett Mapping of Quantitative Trait Loci Determining NK Cell-Mediated Resistance to MHC Class I-Deficient Bone Marrow Grafts in Perforin-Deficient Mice J. Immunol., December 1, 2006; 177(11): 7923 - 7929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Garton, P. J. Gough, and E. W. Raines Emerging roles for ectodomain shedding in the regulation of inflammatory responses J. Leukoc. Biol., June 1, 2006; 79(6): 1105 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Otsuki, Y. Miura, Y. Nishimura, F. Hyodoh, A. Takata, M. Kusaka, H. Katsuyama, M. Tomita, A. Ueki, and T. Kishimoto Alterations of Fas and Fas-Related Molecules in Patients with Silicosis. Experimental Biology and Medicine, May 1, 2006; 231(5): 522 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Hsiao, W.-S. Wang, P.-M. Chen, and Y. Su Overexpression of thymosin {beta}-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively Carcinogenesis, May 1, 2006; 27(5): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-S. Wang, P.-M. Chen, H.-S. Wang, W.-Y. Liang, and Y. Su Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma Carcinogenesis, May 1, 2006; 27(5): 1113 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bremer, B. t. Cate, D. F. Samplonius, L. F. M. H. de Leij, and W. Helfrich CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia Blood, April 1, 2006; 107(7): 2863 - 2870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Lewis and J. W. Pollard Distinct Role of Macrophages in Different Tumor Microenvironments Cancer Res., January 15, 2006; 66(2): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nadal, J. Maurel, R. Gallego, A. Castells, R. Longaron, M. Marmol, S. Sanz, R. Molina, M. Martin-Richard, and P. Gascon FAS/FAS Ligand Ratio: A Marker of Oxaliplatin-Based Intrinsic and Acquired Resistance in Advanced Colorectal Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4770 - 4774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poulaki, C. S. Mitsiades, C. McMullan, G. Fanourakis, J. Negri, A. Goudopoulou, I. X. Halikias, G. Voutsinas, S. Tseleni-Balafouta, J. W. Miller, et al. Human Retinoblastoma Cells Are Resistant to Apoptosis Induced by Death Receptors: Role of Caspase-8 Gene Silencing Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hallermalm, A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes Cancer Res., September 15, 2004; 64(18): 6775 - 6782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Blons, S. Gad, F. Zinzindohoue, I. Maniere, J. Beauregard, D. Tregouet, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig Matrix Metalloproteinase 3 Polymorphism: A Predictive Factor of Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., April 15, 2004; 10(8): 2594 - 2599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Jones, M. J. Humphreys, F. Campbell, J. P. Neoptolemos, and M. T. Boyd Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer: Increased Expression of Matrix Metalloproteinase-7 Predicts Poor Survival Clin. Cancer Res., April 15, 2004; 10(8): 2832 - 2845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Duan, Z. Zhou, S.-F. Jia, M. Colvin, E. A. Lafleur, and E. S. Kleinerman Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway Clin. Cancer Res., January 15, 2004; 10(2): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J R Bebb, D P Letley, R J Thomas, F Aviles, H M Collins, S A Watson, N M Hand, A Zaitoun, and J C Atherton Helicobacter pylori upregulates matrilysin (MMP-7) in epithelial cells in vivo and in vitro in a Cag dependent manner Gut, October 1, 2003; 52(10): 1408 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Burke, A. Giannoudis, K. P. Corke, D. Gill, M. Wells, L. Ziegler-Heitbrock, and C. E. Lewis Hypoxia-Induced Gene Expression in Human Macrophages: Implications for Ischemic Tissues and Hypoxia-Regulated Gene Therapy Am. J. Pathol., October 1, 2003; 163(4): 1233 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Wroblewski, P.-J. M. Noble, A. Pagliocca, D. M. Pritchard, C. A. Hart, F. Campbell, A. R. Dodson, G. J. Dockray, and A. Varro Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration J. Cell Sci., July 15, 2003; 116(14): 3017 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, S. P. Treon, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells PNAS, October 29, 2002; 99(22): 14374 - 14379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Vargo-Gogola, B. Fingleton, H. C. Crawford, and L. M. Matrisian Matrilysin (Matrix Metalloproteinase-7) Selects for Apoptosis-resistant Mammary Cells in Vivo Cancer Res., October 1, 2002; 62(19): 5559 - 5563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hashimoto, I. Inoki, Y. Fujii, T. Aoki, E. Ikeda, and Y. Okada Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165 J. Biol. Chem., September 20, 2002; 277(39): 36288 - 36295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zuo, N. Kaminski, E. Eugui, J. Allard, Z. Yakhini, A. Ben-Dor, L. Lollini, D. Morris, Y. Kim, B. DeLustro, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans PNAS, April 30, 2002; 99(9): 6292 - 6297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sheppard Uses of Expression Microarrays in Studies of Pulmonary Fibrosis, Asthma, Acute Lung Injury, and Emphysema : Roger S. Mitchell Lecture Chest, March 1, 2002; 121(2007): 21S - 25S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Morrison, G. S. Butler, H. F. Bigg, C. R. Roberts, P. D. Soloway, and C. M. Overall Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent Pathway J. Biol. Chem., December 7, 2001; 276(50): 47402 - 47410. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
